New York Life Investment Management LLC Buys 4,717 Shares of Teleflex Incorporated (NYSE:TFX)

New York Life Investment Management LLC increased its holdings in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 63.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,139 shares of the medical technology company's stock after purchasing an additional 4,717 shares during the quarter. New York Life Investment Management LLC's holdings in Teleflex were worth $3,027,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cooke & Bieler LP increased its stake in Teleflex by 5.7% in the fourth quarter. Cooke & Bieler LP now owns 734,965 shares of the medical technology company's stock valued at $183,256,000 after purchasing an additional 39,308 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Teleflex by 23.3% in the third quarter. Invesco Ltd. now owns 621,445 shares of the medical technology company's stock valued at $122,058,000 after acquiring an additional 117,401 shares during the period. TD Asset Management Inc boosted its holdings in shares of Teleflex by 2.5% in the third quarter. TD Asset Management Inc now owns 481,840 shares of the medical technology company's stock valued at $94,638,000 after acquiring an additional 11,796 shares during the period. Northern Trust Corp boosted its holdings in shares of Teleflex by 4.3% in the third quarter. Northern Trust Corp now owns 457,170 shares of the medical technology company's stock valued at $89,793,000 after acquiring an additional 19,001 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Teleflex by 1.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 393,053 shares of the medical technology company's stock valued at $77,200,000 after acquiring an additional 4,415 shares during the period. Hedge funds and other institutional investors own 95.62% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TFX shares. StockNews.com downgraded Teleflex from a "buy" rating to a "hold" rating in a report on Friday, February 23rd. Needham & Company LLC reissued a "hold" rating on shares of Teleflex in a report on Friday. Truist Financial decreased their price objective on Teleflex from $240.00 to $219.00 and set a "hold" rating for the company in a report on Friday. Royal Bank of Canada decreased their price target on Teleflex from $272.00 to $265.00 and set an "outperform" rating for the company in a report on Friday, February 23rd. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $285.00 price target on shares of Teleflex in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $261.75.

Teleflex Price Performance

Shares of NYSE TFX traded down $2.05 during trading on Monday, hitting $200.96. 468,990 shares of the company were exchanged, compared to its average volume of 283,820. The company has a market cap of $9.47 billion, a price-to-earnings ratio of 32.26, a PEG ratio of 1.95 and a beta of 1.13. Teleflex Incorporated has a 1 year low of $177.63 and a 1 year high of $262.97. The firm's fifty day moving average price is $216.73 and its 200 day moving average price is $226.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.51 and a quick ratio of 1.41.

Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical technology company reported $3.21 EPS for the quarter, topping the consensus estimate of $3.07 by $0.14. The company had revenue of $737.80 million for the quarter, compared to analyst estimates of $726.85 million. Teleflex had a net margin of 9.82% and a return on equity of 14.78%. The business's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.09 EPS. On average, sell-side analysts expect that Teleflex Incorporated will post 13.72 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.36 annualized dividend and a dividend yield of 0.68%. Teleflex's payout ratio is currently 21.83%.

Insider Transactions at Teleflex

In other news, VP Cameron P. Hicks sold 7,401 shares of Teleflex stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the transaction, the vice president now owns 10,050 shares of the company's stock, valued at approximately $2,261,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.43% of the company's stock.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.